Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Is Getting Increasingly Hard To Ignore
Currently, there are 255.94M common shares owned by the public and among those 226.52M shares have been available to trade. The company’s stock has a 5-day price change of -16.67% and -56.60% over the past three months. ADAP shares are trading -53.59% year to date (YTD), with the 12-month market performance down to -78.07% lower. […]
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) – Suitable For Long Term Buy?
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling […]